Clinical case of trastuzumab deruxtecan use in treatment of patient with metastatic HER2-positive breast cancer and failure to standard therapy

Currently oncologists have numerous anti-HER2 drugs available, the sequential use of which ensures long-term disease control in metastatic HER2-positive breast cancer. These drugs belong to various classes, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates, which feature a fundamentally new mechanism of action. In these conjugates, the cytostatic agent is linked to the monoclonal antibody via a special linker. This structure allows the monoclonal antibody (trastuzumab) to recognize targeted tumor cells (HER2-positive), bind to the HER2 receptor, and the antibody–receptor complex is then internalized into the cell. The active cytostatic agent is then released and exerts its effect directly on the tumor cell. One of the most effective conjugates to date is trastuzumab deruxtecan (T-DXd). It has been studied in numerous trials and demonstrated high objective response rates, with progression-free survival and overall survival significantly higher than with standard treatment options. This article presents a clinical case of the use of T-DXd as a sixth-line therapy in a patient with metastatic HER2-positive breast cancer involving the lungs and brain, who had failed to respond to previous treatments, a rare occurrence. As the disease progressed, the patient’s cough and shortness of breath worsened with standard treatments, forcing her to leave work and significantly impairing her quality of life. When brain metastases were detected, she was prescribed T-DXd, and for the first time after all treatments, positive dynamics in the lung tumor process were observed, leading to a significant improvement in her well-being.

1. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55–62. https://doi.org/10.5858/2010-0454-RAR.1.

2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. https://doi.org/10.1126/science.3798106.

3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. https://doi.org/10.1056/NEJM200103153441101.

4. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–9336. https://doi.org/10.1158/0008-5472.CAN-08-4597.

5. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. https://doi.org/10.1016/S1470-2045(19)30863-0.

6. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. https://doi.org/10.1056/NEJMoa064320.

7. Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016;2(12):1557–1564. https://doi.org/10.1001/jamaoncol.2016.0237.

8. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597–609. https://doi.org/10.1056/NEJMoa1914609.

9. Marei HE, Cenciarelli C, Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022;22(1):255. https://doi.org/10.1186/s12935-022-02679-8.

10. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124.

11. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–5108. https://doi.org/10.1158/1078-0432.CCR-15-2822.

12. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621. https://doi.org/10.1056/NEJMoa1914510.

13. André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773–1785. https://doi.org/10.1016/S0140-6736(23)00725-0.

14. Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12):991–1000. https://doi.org/10.1038/s41416-019-0619-y.

15. Chhichholiya Y, Ruthuparna M, Velagaleti H, Munshi A. Brain metastasis in breast cancer: focus on genes and signaling pathways involved, bloode-brain barrier and treatment strategies. Clin Transl Oncol. 2023;25(5):1218–1241. https://doi.org/10.1007/s12094-022-03050-z.

16. Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350–1358. https://doi.org/10.1016/j.annonc.2020.06.020.

17. Pérez-García JM, Batista MV, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023;25(1):157–166. https://doi.org/10.1093/neuonc/noac144.

18. Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–1847. https://doi.org/10.1038/s41591-022-01935-8.

19. Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380–1388. https://doi.org/10.1016/S1470-2045(15)00135-7.

20. Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141–3149. https://doi.org/10.1245/s10434-018-6494-6.

21. Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS et al . 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. https://doi.org/10.1016/j.breast.2024.103756.

22. Hurvitz SA, Modi S, Li W, Park YH, Chung W, Kim SB et al. 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. Ann Oncol. 2023;34(S2):S335–S336. https://doi.org/10.1016/j.annonc.2023.09.554.